计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
Miransertib (ARQ 092) HCl is a novel, orally bioavailable and selectiveAKT pathwayinhibitor exhibiting a manageable safety profile among patients with advanced solid tumors.
Targets
Akt2 (Cell-free assay); Akt1 (Cell-free assay); Akt3 (Cell-free assay) 4.5 nM; 5 nM; 16 nM
In vitro
ARQ 092 blocks membrane translocation of inactive AKT and even dephosphorylates the membrane-associated active form, thereby perturbing AKT activity. Treatment with 50-500 nM ARQ 092 significantly blocks αMβ2 integrin function in neutrophils and reduces P-selectin exposure and glycoprotein Ib/IX/V-mediated agglutination in platelets. In a large panel of diverse cancer cell lines, ARQ 092 inhibits proliferation across multiple tumor types but are most potent in leukemia, breast, endometrial, and colorectal cancer cell lines. Moreover, inhibition by ARQ 092 is more prevalent in cancer cell lines containing PIK3CA/PIK3R1 mutations compared to those with wt-PIK3CA/PIK3R1 or PTEN mutations. ARQ 092 targets the PI3K/AKT pathway and AKT specifically and reduces phosphorylation of GSK3α and GSK3β in mutation-positive cells.
In vivo
Short-term oral administration of ARQ 092 or hydroxyurea, a main therapy for sickle cell disease, diminishes heterotypic cell-cell interactions in venules of sickle cell disease mice challenged with TNF-α. ARQ 092 is well tolerated at a continuous daily dose of 60 mg or a dose of 600 mg when administered once a week, for several months. ARQ 092 is likely to inhibit the activity of all AKT isoforms in intravascular cells and thereby attenuates the process of thrombosis and inflammation in SCD patients. ARQ 092 is highly active in a subset of endometrial tumors that harbor PI3K pathway gene mutations.
Cell Research(from reference)
Cell lines:MDA-MB-453 cells; NCI-H1650 cells; KU-19-19 cells
Concentrations:0, 0.012, 0.037, 0.11, 0.33, and 1 μM
Incubation Time:2 h
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 吡啶及其衍生物 |
| 亚类(Subclass) | 苯基吡啶 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 苯基吡啶 |
| 其他上位类(Alternative Parents) | 苯基咪唑类 咪唑并吡啶类 芳烷基胺 氨基吡啶及其衍生物 N-取代咪唑 咪唑内酰胺类 苯及其取代衍生物 杂芳族化合物 氮杂环化合物 单烷基胺 盐酸盐 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 1-苯基咪唑 - 2-苯基吡啶 - 氨基酸 - 氨基吡啶 - 芳烷基胺 - 芳香族杂多环化合物 - 氮杂环 - 吡唑 - 苯基化合物 - 杂芳香族化合物 - 烃衍生物 - 氟氯烃 - 咪唑 - 咪唑吡啶酮 - 咪唑内酰胺 - 单环苯基基团 - N-取代咪唑 - 有机硝基化合物 - 有机氮化合物 - 初级脂肪胺 - 初级胺 |
| 描述(Description) | 该化合物属于苯并吡啶类有机化合物。这类多环芳烃通过碳碳键或氰键将苯环与吡啶环相连。 |
| 外部描述符(External Descriptors) | 暂无 |
| IC50 | Akt2, IC50: 4.5 nM |
|---|---|
| ALogP | 4.98 |
| hba_count | 3 |
| HBD Count | 2 |
| Rotatable Bond | 4 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
H302: 吞食有害
H315: 引起皮肤刺激
H319: 引起严重眼睛刺激
H335: 可能引起呼吸道刺激
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾
P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 | |
| 分析证书 | M413976 |